ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical role of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer (GC) remains controversial. This single-center study evaluated the clinical outcomes of gastrectomy after systemic cancer therapy in cStage IVB GC to identify prognosis-predicting factors.
methodsWe retrospectively reviewed patients with cStage IVB GC who received systemic cancer therapy as initial treatment from 2013 to 2023 and subsequently underwent gastrectomy. Patients were categorized as having oligometastatic disease or polymetastatic disease based on pre-treatment disease status. Survival outcomes and prognostic factors were analyzed.
resultsAmong 1,591 patients who received systemic cancer therapy, 121 (7.6%) underwent gastrectomy (79 oligometastatic disease and 42 polymetastatic disease). The 3-year overall survival (OS) rate was 65% for the entire cohort. Patients with oligometastatic disease had better survival than those with polymetastatic disease (3-year OS: 76% vs. 43%, p = 0.009). Major pathological response (MPR) was observed in 39 patients (32%) and was associated with favorable survival in both oligometastatic (3-year OS: 97%) and polymetastatic disease (3-year OS: 89%). Further stratification showed similarly favorable survival in patients with clinical complete response and those without clinical complete response but with MPR, whereas patients without either response had poor outcomes (3-year OS: 94%, 95%, and 50%, respectively; p < 0.001).
conclusionsPostoperative prognosis after gastrectomy for cStage IVB GC appears to depend largely on pretreatment metastatic status and extent of response to systemic therapy. Technical resectability alone may be insufficient for surgical decision-making, particularly in polymetastatic disease.
Indexed as
Identifiers
42645632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.